The current financial score of Neurogene Inc is 5.49. Its financial status is weak, and its operating efficiency is low.
The current valuation score of Neurogene Inc is 7.52. Its current P/E ratio is -6.81, which is -905.91% below the recent high of 54.85 and -164.09% above the recent low of -17.97.
The current earnings forecast score of Neurogene Inc is 8.89. The average price target is 80.43, with a high of 166.00 and a low of 46.00.
The current price momentum score of Neurogene Inc is 4.66. Currently, the stock price is trading between the resistance level at 38.40 and the support level at 26.83, making it suitable for range-bound swing trading.
The current institutional shareholding score of Neurogene Inc is 10.00. The latest institutional shareholding proportion is 113.37%, representing a quarter-over-quarter increase of 4.87%.
The current risk assessment score of Neurogene Inc is 4.85. The company's beta value is 1.70. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.